Practical considerations for the treatment of elderly patients with migraine

Drugs and Aging

Volumn 23, Issue 6, 2006, Pages 461-489

  Sarchielli, Paola ^a,b   Mancini, Maria Luisa ^a   Calabresi, Paolo ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b Ospedale Silvestrini   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANALGESIC AGENT; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIEMETIC AGENT; ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLUNARIZINE; IBUPROFEN; MAGNESIUM; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PARACETAMOL; PROPRANOLOL DERIVATIVE; RIBOFLAVIN; ROFECOXIB; SEROTONIN 1B ANTAGONIST; SEROTONIN 1D ANTAGONIST; SEROTONIN ANTAGONIST; SEROTONIN UPTAKE INHIBITOR; TANACETUM PARTHENIUM EXTRACT; TRICYCLIC ANTIDEPRESSANT AGENT; UBIDECARENONE; UNINDEXED DRUG; VERAPAMIL;

ABDOMINAL PAIN; ANOREXIA; ATRIOVENTRICULAR BLOCK; CARDIOVASCULAR RISK; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; COMORBIDITY; CONSTIPATION; DEPRESSION; DIABETES MELLITUS; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FLUSHING; GASTRITIS; GASTROINTESTINAL SYMPTOM; GLAUCOMA; HEART DISEASE; HEART FAILURE; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; MENOPAUSE; MIGRAINE; MOOD DISORDER; NAUSEA; PALLIATIVE THERAPY; PARKINSON DISEASE; PEPTIC ULCER; PERIPHERAL VASCULAR DISEASE; PRIORITY JOURNAL; PROPHYLAXIS; PROSTATISM; REVIEW; SEDATION; SEROTONIN SYNDROME; SIDE EFFECT; SOMNOLENCE; TASTE DISORDER; TREATMENT INDICATION; VOMITING; WEIGHT GAIN;

AGED; ANALGESICS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIEMETICS; HORMONE REPLACEMENT THERAPY; HUMANS; MENOPAUSE; MIGRAINE DISORDERS; PHARMACEUTICAL PREPARATIONS; SEROTONIN AGONISTS; SEROTONIN RECEPTOR AGONISTS; TRYPTAMINES;

EID: 33746666618     PISSN: 1170229X     EISSN: 1170229X     Source Type: Journal    
DOI: 10.2165/00002512-200623060-00003     Document Type: Review

References (239)

1. Prencipe M, Casini AR, Ferretti C, et al. Prevalence of headache in an elderly population: attack frequency, disability, and use of medication. J Neurol Neurosurg Psychiatry 2001; 70 (3): 377-81
2. Camarda R, Monastero R. Prevalence of primary headaches in Italian elderly: preliminary data from the Zabut Aging Project. Neurol Sci 2003; 24 Suppl. 2: S122-S4
3. Wang SJ, Liu HC, Fuh JL, et al. Prevalence of headaches in a Chinese elderly population in Kinmen: age and gender effect and cross-cultural comparisons. Neurology 1997; 49 (1): 195-200
4. Lipton RB, Pfeffer D, Newman LC, et al. Headaches in the elderly. J Pain Symptom Manage 1993; 8 (2): 87-97
5. Chatap G, Giraud K, Vincent JP, et al. Headaches in the elderly [in French]. Presse Med 2004; 33 (12 Pt 1): 808-18
6. Edmeads J, Wang SJ. Headaches in the elderly. In: Olesen J, Goadsby P, Ramadan NM, et al., editors. The headaches. 3rd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2006: 1105-10
7. Edmeads J. Headaches in older people: how are they different in this age-group? Postgrad Med 1997; 101 (5): 91-4, 98-100
8. Biondi DM, Saper JR. Geriatric headache: how to make the diagnosis and manage the pain. Geriatrics 2000; 55 (12): 40, 43-5, 48-50
9. Evers S, Goadsby PJ. Hypnic headache: clinical features, pathophysiology, and treatment. Neurology 2003; 60 (6): 905-9
10. Mattsson P, Sv̈ardsudd K, Lundberg PO, et al. The prevalence of migraine in women aged 40-70 years: a population-based study. Cephalalgia 2000; 20 (10): 893-9
11. Lipton RB, Stewart WF. The epidemiology of migraine. Eur Neurol 1994; 34 Suppl. 2: 6-11
12. Stewart WF, Lipton RB, Celentano DD, et al. Prevalence of migraine headache in the United States. JAMA 1992; 267 (1): 64-9
13. Cull RE. Investigation of late-onset migraine. Scott Med J 1995; 40 (2): 50-2
14. Mazzotta G, Gallai V, Alberti A, et al. Characteristics of migraine in an out-patient population over 60 years of age. Cephalalgia 2003; 23 (10): 953-60
15. Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996; 47 (4): 871-5
16. Fisher CM. Late-life (migrainous) scintillating zigzags without headache: one person's 27-year experience. Headache 1999; 39 (6): 391-7
17. Martins KM, Bordini CA, Bigal ME, et al. Migraine in the elderly: a comparison with migraine in young adults. Headache 2006; 46 (2): 312-6
18. Wynne H. Drug metabolism and ageing. J Br Menopause Soc 2005; 11 (2): 51-6
19. Rankin LM, Bruhl M. Migraine in older patients: a case report and management strategies. Geriatrics 2000; 55 (7): 70-4
20. Landy S. Migraine throughout the life cycle: treatment through the ages. Neurology 2004; 62 (5 Suppl. 2): S2-8
21. Pietrini U, De Luca M, De Santis G. Hypertension in headache patients? A clinical study. Acta Neurol Scand 2005; 112 (4): 259-64
22. Tzourio C, Gagniere B, El Amrani M, et al. Relationship between migraine, blood pressure and carotid thickness: a population-based study in the elderly. Cephalalgia 2003; 23 (9): 914-20
23. Gilbert GJ. Cardiac cephalgia. Neurology 1998; 50 (3): 836
24. Green MW. A spectrum of exertional headaches. Med Clin North Am 2001; 85 (4): 1085-92
25. Cook NR, Bensenor IM, Lotufo PA, et al. Migraine and coronary heart disease in women and men. Headache 2002; 42 (8): 715-27
26. Logroscino G, Lipton RB. Migraine is associated with chest symptoms but not cardiac events: a reassuring paradox [letter]. Neurology 2004; 63 (12): 2209-10
27. O'Keeffe ST, Tsapatsaris NP, Beetham Jr WP. Association between Raynaud's phenomenon and migraine in a random population of hospital employees. J Rheumatol 1993; 20 (7): 1187-8
28. Rosamond W. Are migraine and coronary heart disease associated? An epidemiologic review. Headache 2004; 44 Suppl. 1: S5-S12
29. Etminan M, Takkouche B, Isorna FC, et al. Risk of ischaemic stroke in people with migraine: systematic review and meta-analysis of observational studies [published erratum appears in BMJ 2005; 330 (7487): 345; BMJ 2005; 330 (7491): 596]. BMJ 2005; 330 (7482): 63
30. Kurth T, Slomke MA, Kase CS, et al. Migraine, headache, and the risk of stroke in women: a prospective study. Neurology 2005; 64 (6): 1020-6
31. Bousser MG, Welch KM. Relation between migraine and stroke. Lancet Neurol 2005; 4 (9): 533-42
32. Wiehe M, Fuchs SC, Moreira LB, et al. Migraine is more frequent in individuals with optimal and normal blood pressure: a population-based study. J Hypertens 2002; 20 (7): 1303-6
33. Silvestrini M. Migrainous stroke and antiphospholipid antibodies: are they pathogenetically linked? [letter]. Eur Neurol 1996; 36 (2): 114
34. Tietjen GE. The risk of stroke in patients with migraine and implications for migraine management. CNS Drugs 2005; 19 (8): 683-92
35. Crassard I, Conard J, Bousser MG. Migraine and haemostasis. Cephalalgia 2001; 21 (6): 630-6
36. Diener HC, Weimar C, Katsarava Z. Patent foramen ovale: paradoxical connection to migraine and stroke. Curr Opin Neurol 2005; 18 (3): 299-304
37. Kruit MC, Launer LJ, van Buchem MA, et al. MRI findings in migraine [in French]. Rev Neurol (Paris) 2005; 161 (6-7): 661-5
38. Goadsby PJ. Is migraine a progressive disorder? Considering the clinical implications of new research data on migraine and brain lesions. Med J Aust 2005; 182 (3): 103-4
39. Khaghan N, Holt PR. Peptic disease in elderly patients. Can J Gastroenterol 2000; 14 (11): 922-8
40. Pilotto A. Aging and upper gastrointestinal disorders. Best Pract Res Clin Gastroenterol 2004; 18 Suppl.: 73-81
41. Alexopoulos GS. Depression in the elderly. Lancet 2005; 365 (9475): 1961-70
42. Wang SJ, Liu HC, Fuh JL, et al. Comorbidity of headaches and depression in the elderly. Pain 1999; 82 (3): 239-43
43. de Bock GH, Eelhart J, van Marwijk HW, et al. A postmarketing study of flunarizine in migraine and vertigo. Pharm World Sci 1997; 19 (6): 269-74
44. Ellison KE, Gandhi G. Optimising the use of beta-adrenoceptor antagonists in coronary artery disease. Drugs 2005; 65 (6): 787-97
45. Becker WJ. Evidence based migraine prophylactic drug therapy. Can J Neurol Sci 1999; 26 Suppl. 3: 27S-32S
46. Zanardi R, Artigas F, Franchini L, et al. How long should pindolol be associated with paroxetine to improve the antidepressant response? J Clin Psychopharmacol 1997; 17 (6): 446-50
47. Patten SB, Barbui C. Drug-induced depression: a systematic review to inform clinical practice. Psychother Psychosom 2004; 73 (4): 207-15
48. Higelin F, Annoni JM. Medical treatment of migraine: from mechanisms of action to contraindications. Schweiz Med Wochenschr 1998; 128 (10): 374-83
49. Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 2005; 45 (10): 1106-22
50. Petrovic M, De Paepe P, Van Bortel L. Pharmacotherapy of depression in old age. Acta Clin Belg 2005; 60 (3): 150-6
51. Westenberg HG, Sandner C. Tolerability and safety of fluvoxamine and other antidepressants. Int J Clin Pract 2006; 60 (4): 482-91
52. Briesacher BA, Stuart B, Peluso R. Drug use and prescribing problems in the community-dwelling elderly: a study of three state Medicaid programs. Clin Ther 1999; 21 (12): 2156-72
53. Eadie MJ. Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs 2001; 15 (2): 105-18
54. Avoiding drug interactions. Prescrire Int 2004; 13 (71): 99-102
55. Toth C. Medications and substances as a cause of headache: a systematic review of the literature. Clin Neuropharmacol 2003; 26 (3): 122-36
56. Landy SH. Challenging or difficult headache patients. Prim Care 2004; 31 (2): 429-40
57. Blanchard EB, Andrasik F, Evans DD, et al. Biofeedback and relaxation treatments for headache in the elderly: a caution and a challenge. Biofeedback Self Regul 1985; 10 (1): 69-73
58. Kabela E, Blanchard EB, Appelbaum KA, et al. Self-regulatory treatment of headache in the elderly. Biofeedback Self Regul 1989; 14 (3): 219-28
59. Ad Hoc Committee of the Italian Society for the Study of Headaches (SISC). Diagnostic and therapeutic guidelines for migraine and cluster headache. J Headache Pain 2001; 2 (3): 105-92
60. Blau JN. Migraine triggers: practice and theory [in French]. Pathol Biol (Paris) 1992; 40 (4): 367-72
61. Sheftell FD, Cady RK, Borchert LD, et al. Optimizing the diagnosis and treatment of migraine. J Am Acad Nurse Pract 2005; 17 (8): 309-17
62. Deleu D, Hanssens Y, Worthing EA. Symptomatic and prophylactic treatment of migraine: a critical reappraisal. Clin Neuropharmacol 1998; 21 (5): 267-79
63. Pfaffenrath V, Scherzer S. Analgesics and NSAIDs in the treatment of the acute migraine attack. Cephalalgia 1995; 15 Suppl. 15: 14-20
64. Peterson GM. Selecting nonprescription analgesics. Am J Ther 2005; 12 (1): 67-79
65. Ohnishi A, Murakami S, Akizuki S, et al. In vivo metabolic activity of CYP2C19 and CYP3A in relation to CYP2C19 genetic polymorphism in chronic liver disease. J Clin Pharmacol 2005; 45 (11): 1221-9
66. Lauterburg BH. Analgesics and glutathione. Am J Ther 2002; 9 (3): 225-33
67. Benson GD, Koff RS, Tolman KG. The therapeutic use of acetaminophen in patients with liver disease. Am J Ther 2005; 12 (2): 133-41
68. Diener HC, Limmroth V. Analgesics. Curr Med Res Opin 2001; 17 Suppl. 1: 13S-6S
69. Rasmussen MK, Binzer M. Non-steroidal anti-inflammatory drugs in the treatment of migraine. Curr Med Res Opin 2001; 17 Suppl. 1: 26S-9S
70. Wenzel RG, Sarvis CA, Krause ML. Over-the-counter drugs for acute migraine attacks: literature review and recommendations. Pharmacotherapy 2003; 23 (4): 494-505
71. Dalton SO, Sorensen HT, Johansen C. SSRIs and upper gastrointestinal bleeding: what is known and how should it influence prescribing? CNS Drugs 2006; 20 (2): 143-51
72. Go MF. Drug injury in the upper gastrointestinal tract: nonsteroidal anti-inflammatory drugs. Gastrointest Endosc Clin N Am 2006; 16 (1): 83-97
73. Herings RM, Goettsch WG. Inadequate prevention of NSAID-induced gastrointestinal events. Ann Pharmacother 2004; 38 (5): 760-3
74. Wolfe F, Anderson J, Burke TA, et al. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy. J Rheumatol 2002; 29 (3): 467-73
75. Rybar I, Masaryk P, Mateicka F, et al. Nonsteroidal antiinflammatory drug-induced mucosal lesions of the upper gastrointestinal tract and their relationship to Helicobacter pylori. Int J Clin Pharmacol Res 2001; 21 (3-4): 119-25
76. Hawkey CJ, Fortun PJ. Cyclooxygenase-2 inhibitors. Curr Opin Gastroenterol 2005; 21 (6): 660-4
77. Krymchantowski AV, Bigal ME. Rofecoxib in migraine. Expert Rev Neurother 2005; 5 (1): 55-61
78. Misra UK, Jose M, Kalita J. Rofecoxib versus ibuprofen for acute treatment of migraine: a randomised placebo controlled trial. Postgrad Med J 2004; 80 (950): 720-3
79. Krotz F, Schiele TM, Klauss V, et al. Selective COX-2 inhibitors and risk of myocardial infarction. J Vasc Res 2005; 42 (4): 312-24
80. Batty GM, Oborne CA, Swift CG, et al. The use of over-the-counter medication by elderly medical inpatients. Postgrad Med J 1997; 73 (865): 720-2
81. Francis SA, Barnett N, Denham M. Switching of prescription drugs to over-the-counter status: is it a good thing for the elderly? Drugs Aging 2005; 22 (5): 361-70
82. Ward TN. Medication overuse headache. Prim Care 2004; 31 (2): 369-80
83. Bigal ME, Sheftell FD, Rapoport AM, et al. Chronic daily headache: identification of factors associated with induction and transformation. Headache 2002; 42 (7): 575-81
84. Grazzi L, Andrasik F. Medication-overuse headache: description, treatment, and relapse prevention. Curr Pain Headache Rep 2006; 10 (1): 71-7
85. Poole C, Jones D, Veitch B. Relationships between prescription and non-prescription drug use in an elderly population. Arch Gerontol Geriatr 1999; 28 (3): 259-71
86. Roumie CL, Griffin MR. Over-the-counter analgesics in older adults: a call for improved labelling and consumer education. Drugs Aging 2004; 21 (8): 485-98
87. Neubauer DN. Sleep problems in the elderly. Am Fam Physician 1999; 59 (9): 2551-8, 2559-60
88. Smith A. Effects of caffeine on human behavior. Food Chem Toxicol 2002; 40 (9): 1243-55
89. Loder E. Fixed drug combinations for the acute treatment of migraine: place in therapy. CNS Drugs 2005; 19 (9): 769-84
90. Wilder-Smith OH. Opioid use in the elderly. Eur J Pain 2005; 9 (2): 137-40
91. Silberstein SD, McCrory DC. Opioids. Cephalalgia 2000; 20 (10): 854-64
92. Ziegler DK. Opioids in headache treatment: is there a role? Neurol Clin 1997; 15 (1): 199-207
93. Adelman JU, Lewit EJ. Comparative aspects of triptans in treating migraine. Clin Cornerstone 2001; 4 (3): 53-64
94. Rapoport AM, Tepper SJ, Bigal ME, et al. The triptan formulations: how to match patients and products. CNS Drugs 2003; 17 (6): 431-47
95. Tepper SJ, Millson D. Safety profile of the triptans. Expert Opin Drug Saf 2003; 2 (2): 123-32
96. Hall GC, Brown MM, Mo J, et al. Triptans in migraine: the risks of stroke, cardiovascular disease, and death in practice. Neurology 2004; 62 (4): 563-8
97. Dodick D, Lipton RB, Martin V, et al., on behalf of the Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 2004; 44 (5): 414-25
98. Papademetriou V. Cardiovascular risk assessment and triptans. Headache 2004; 44 Suppl. 1: 31S-9S
99. Tepper S, Allen C, Sanders D, et al. Coprescription of triptans with potentially interacting medications: a cohort study involving 240,268 patients. Headache 2003; 43 (1): 44-8
100. MacGregor EA. Anti-emetics. Curr Med Res Opin 2001; 17 Suppl. 1: 22S-5S
101. Jimenez-Jimenez FJ, Garcia-Ruiz PJ, Molina JA. Drug-induced movement disorders. Drug Saf 1997; 16 (3): 180-204
102. Green JF, McElholm A, King DJ. A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam. Psychopharmacology (Berl) 1996; 128 (1): 67-73
103. Hedges D, Jeppson K, Whitehead P. Antipsychotic medication and seizures: a review. Drugs Today (Barc) 2003; 39 (7): 551-7
104. Gladstone JP, Eross EJ, Dodick DW. Migraine in special populations: treatment strategies for children and adolescents, pregnant women, and the elderly. Postgrad Med 2004; 115 (4): 39-44, 47-50
105. Blumenfeld A. Clinical approaches to migraine prophylaxis. Am J Manag Care 2005; 11 (2 Suppl.): 55S-61S
106. Pryse-Phillips WE, Dodick DW, Edmeads JG, et al. Guidelines for the diagnosis and management of migraine in clinical practice. Canadian Headache Society. CMAJ 1997; 156 (9): 1273-87
107. Morey SS. Guidelines on migraine: part 5. Recommendations for specific prophylactic drugs. Am Fam Physician 2000; 62 (11): 2535-9
108. Ramadan NM, Silberstein SD, Freitag FG, et al. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine [online]. Available from URL: http://www.aan.com/ professionals/practice/guideline/index.cfm [Accessed 2006 May 19]
109. Geraud G, Lanteri-Minet M, Lucas C, et al., on behalf of the French Society for the Study of Migraine Headache (SFEMC). French guidelines for the diagnosis and management of migraine in adults and children. Clin Ther 2004; 26 (8): 1305-18
110. Landy SH, Lobo BL. Migraine treatment throughout the life-cycle. Expert Rev Neurother 2005; 5 (3): 343-53
111. Scher AI, Bigal ME, Lipton RB. Comorbidity of migraine. Curr Opin Neurol 2005; 18 (3): 305-10
112. Silberstein SD. Preventive treatment of headaches. Curr Opin Neurol 2005; 18 (3): 289-92
113. Lucetti C, Nuti A, Pavese N, et al. Flunarizine in migraine prophylaxis: predictive factors for a positive response. Cephalalgia 1998; 18 (6): 349-52
114. Schmidt R, Oestreich W. Flunarizine in migraine prophylaxis: the clinical experience. J Cardiovasc Pharmacol 1991; 18 Suppl. 8: S21-6
115. Bender WI. ACE inhibitors for prophylaxis of migraine headaches. Headache 1995; 35 (8): 470-1
116. Montgomery L. Are angiotensin-converting enzyme (ACE) inhibitors effective in preventing migraine in nonhypertensive patients? J Fam Pract 2001; 50 (4): 299
117. Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. BMJ 2001; 322 (7277): 19-22
118. Tronvik E, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA 2003; 289 (1): 65-9
119. Chronicle E, Mulleners W. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev 2004; (3): CD003226
120. Yoon MS, Savidou I, Diener HC, et al. Evidence-based medicine in migraine prevention. Expert Rev Neurother 2005; 5 (3): 333-41
121. Spierings EL. Mechanism of migraine and action of antimigraine medications. Med Clin North Am 2001; 85 (4): 943-58
122. McCrory DC, Matchar DB, Gray RN, et al. Evidence-based guidelines for migraine headache: overview of program description and methodology [online]. Available from URL: http://www.aan.com/professionals/practice/guideline/index. cfm [Accessed 2006 May 19]
123. Limmroth V, Michel MC. The prevention of migraine: a critical review with special emphasis on beta-adrenoceptor blockers. Br J Clin Pharmacol 2001; 52 (3): 237-43
124. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochrane Database Syst Rev 2004; (2): CD003225
125. Zesiewicz TA, Elble R, Louis ED, et al., on behalf of the Quality Standards Subcommittee of the American Academy of Neurology. Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2005; 64 (12): 2008-20
126. Gleiter CH, Deckert J. Adverse CNS-effects of beta-adrenoceptor blockers. Pharmacopsychiatry 1996; 29 (6): 201-11
127. Fullerton T. Recent advances in the understanding and treatment of migraine. Pharmacy Pract 1993; 6: 53-270
128. Lance JW. Treatment of migraine. Lancet 1992; 339 (8803): 1207-9
129. Punay NC, Couch JR. Antidepressants in the treatment of migraine headache. Curr Pain Headache Rep 2003; 7 (1): 51-4
130. Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999; 15 (1): 15-28
131. Colombo B, Annovazzi PO, Comi G. Therapy of primary headaches: the role of antidepressants. Neurol Sci 2004; 25 Suppl. 3: 171S-5S
132. Ramadan NM. Prophylactic migraine therapy: mechanisms and evidence. Curr Pain Headache Rep 2004; 8 (2): 91-5
133. Oguzhanoglu A, Sahiner T, Kurt T, et al. Use of amitriptyline and fluoxetine in prophylaxis of migraine and tension-type headaches. Cephalalgia 1999; 19 (5): 531-2
134. Landy S, McGinnis J, Curlin D, et al. Selective serotonin reuptake inhibitors for migraine prophylaxis. Headache 1999; 39 (1): 28-32
135. Moja P, Cusi C, Sterzi R, et al. Selective serotonin re-uptake inhibitors (SSRIs) for preventing migraine and tension-type headaches. Cochrane Database Syst Rev 2005; (3): CD002919
136. Adelman LC, Adelman JU, Von Seggern R, et al. Venlafaxine extended release (XR) for the prophylaxis of migraine and tension-type headache: a retrospective study in a clinical setting. Headache 2000; 40 (7): 572-80
137. Ozyalcin SN, Talu GK, Kiziltan E, et al. The efficacy and safety of venlafaxine in the prophylaxis of migraine. Headache 2005; 45 (2): 144-52
138. Bulut S, Berilgen MS, Baran A, et al. Venlafaxine versus amitriptyline in the prophylactic treatment of migraine: randomized, double-blind, crossover study. Clin Neurol Neurosurg 2004; 107 (1): 44-8
139. Finfgeld DL. Serotonin syndrome and the use of SSRIs. J Psychosoc Nurs Ment Health Serv 2004; 42 (2): 16-20
140. van Zwieten PA. Protective effects of calcium antagonists in different organs and tissues. Am Heart J 1993; 125 (2 Pt 2): 566-71
141. Grossman E, Messerli FH. Calcium antagonists. Prog Cardiovasc Dis 2004; 47 (1): 34-57
142. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160mg daily [published erratum appears in Cephalalgia 2002; 22 (6): 488]. Cephalalgia 2002; 22 (3): 209-21
143. Berilgen MS, Bulut S, Gonen M, et al. Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment. Cephalalgia 2005; 25 (11): 1048-53
144. Verspeelt J, De Locht P, Amery WK. Post-marketing cohort study comparing the safety and efficacy of flunarizine and propranolol in the prophylaxis of migraine. Cephalalgia 1996; 16 (5): 328-36
145. Daniel JR, Mauro VF. Extrapyramidal symptoms associated with calcium-channel blockers. Ann Pharmacother 1995; 29 (1): 73-5
146. Negrotti A, Calzetti S. A long-term follow-up study of cinnarizine- and flunarizine-induced parkinsonism. Mov Disord 1997; 12 (1): 107-10
147. Facchinetti F, Sances G, Bakalakis C, et al. Neuroendocrine effects of flunarizine treatment in postmenopausal women. Cephalalgia 1985; 5 Suppl. 2: 187-8
148. Spierings EL, Messinger HB. Flunarizine vs. pizotifen in migraine prophylaxis: a review of comparative studies. Cephalalgia 1988; 8 Suppl. 8: 27-30
149. Mylecharane EJ. 5-HT2 receptor antagonists and migraine therapy. J Neurol 1991; 238 Suppl. 1: 45S-52S
150. Silberstein SD. Methysergide. Cephalalgia 1998; 18 (7): 421-35
151. Diener HC, Kaube H, Limmroth VA. Practical guide to the management and prevention of migraine. Drugs 1998; 56 (5): 811-24
152. Wheeler SD. Antiepileptic drug therapy in migraine headache. Curr Treat Options Neurol 2002; 4 (5): 383-94
153. Steinberg J. Anticonvulsant medications for migraine prevention. Am Fam Physician 2005; 71 (9): 1699-700
154. Freitag FG. Divalproex in the treatment of migraine. Psychopharmacol Bull 2003; 37 Suppl. 2: 98-115
155. Silberstein SD. Topiramate in migraine prevention. Headache 2005; 45 Suppl. 1: 57S-65S
156. Young WB, Hopkins MM, Shechter AL, et al. Topiramate: a case series study in migraine prophylaxis. Cephalalgia. 2002; 22 (8): 659-63
157. Topiramate (Topamax) for prevention of migraine. Med Lett Drugs Ther 2005; 47 (1201): 9-10
158. Mattson RH. Cognitive, affective, and behavioral side events in adults secondary to antiepileptic drug use. Rev Neurol Dis 2004; 1 Suppl. 1: 10S-7S
159. Ondo WG, Jankovic J, Connor GS, et al., on behalf of the Topiramate Essential Tremor Study Investigators. Topiramate in essential tremor: a double-blind, placebo-controlled trial. Neurology 2006; 66 (5): 672-7
160. Cereza G, Pedros C, Garcia N, et al. Topiramate in non-approved indications and acute myopia or angle closure glaucoma. Br J Clin Pharmacol 2005; 60 (5): 578-9
161. D'Andrea G, Granella F, Cadaldini M, et al. Effectiveness of lamotrigine in the prophylaxis of migraine with aura: an open pilot study. Cephalalgia 1999; 19 (1): 64-6
162. Lampl C, Buzath A, Klinger D, et al. Lamotrigine in the prophylactic treatment of migraine aura: a pilot study. Cephalalgia 1999; 19 (1): 58-63
163. Steiner TJ, Findley LJ, Yuen AW. Lamotrigine versus placebo in the prophylaxis of migraine with and without aura. Cephalalgia 1997; 17 (2): 109-12
164. Rompel H, Bauermeister PW. Aetiology of migraine and prevention with carbamazepine (Tegretol): results of a double-blind, cross-over study. S Afr Med J 1970; 44 (4): 75-80
165. Frediani F. Anticonvulsant drugs in primary headaches prophylaxis. Neurol Sci 2004; 25 Suppl. 3: 161S-6S
166. Schoonman GG, Wiendels NJ, Ferrari MD. Gabapentin in migraine prophylaxis: is it effective and well tolerated? [letter]. Headache 2002; 42 (3): 235
167. Mathew NT, Rapoport A, Saper J, et al. Efficacy of gabapentin in migraine prophylaxis. Headache 2001; 41 (2): 119-28
168. Freitag FG, Diamond S, Solomon GD. The prophylaxis of migraine with the GABA-agonist tiagabine: a clinical report [abstract]. Headache 1999; 19: 354
169. Drake Jr ME, Greathouse NI, Renner JB, et al. Open-label zonisamide for refractory migraine. Clin Neuropharmacol 2004; 27 (6): 278-80
170. Cochran JW. Levetiracetam as migraine prophylaxis. Clin J Pain 2004; 20 (3): 198-9
171. Capuano A, Vollono C, Mei D, et al. Antiepileptic drugs in migraine prophylaxis: state of the art. Clin Ter 2004; 155 (2-3): 79-87
172. Bergey GK. Initial treatment of epilepsy: special issues in treating the elderly. Neurology 2004; 63 (10 Suppl. 4): 40S-8S
173. Pappagallo M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin Ther 2003; 25 (10): 2506-38
174. Beghi E. Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. Lancet Neurol 2004; 3 (10): 618-21
175. Young WB, Siow HC, Silberstein SD. Anticonvulsants in migraine. Curr Pain Headache Rep 2004; 8 (3): 244-50
176. Zareba G. Zonisamide: review of its use in epilepsy therapy. Drugs Today (Barc) 2005; 41 (9): 589-97
177. Armijo JA, Shushtarian M, Valdizan EM, et al. Ion channels and epilepsy. Curr Pharm Des 2005; 11 (15): 1975-2003
178. Spina E, Perugi G. Antiepileptic drugs: indications other than epilepsy. Epileptic Disord 2004; 6 (2): 57-75
179. Lieberman DZ, Goodwin FK. Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders. Curr Psychiatry Rep 2004; 6 (6): 459-65
180. Muzina DJ, Elhaj O, Gajwani P, et al. Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder. Acta Psychiatr Scand Suppl 2005; (426): 21-8
181. Rahimtoola H, Buurma H, Tijssen CC, et al. Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy: a pilot study. Pharmacoepidemiol Drug Saf 2004; 13 (1): 41-7
182. Diener HC, Hartung E, Chrubasik J, et al., on behalf of the Study Group. A comparative study of oral acetylsalicyclic acid and metoprolol for the prophylactic treatment of migraine: a randomized, controlled, double-blind, parallel group phase III study. Cephalalgia 2001; 21 (2): 120-8
183. Bellavance AJ, Meloche JP. A comparative study of naproxen sodium, pizotyline and placebo in migraine prophylaxis. Headache 1990; 30 (11): 710-5
184. Solomon GD, Kunkel RS. Flurbiprofen in the prophylaxis of migraine. Cleve Clin J Med 1993; 60 (1): 43-8
185. Carrieri PB, Orefice G, Sorge F. A double-blind placebo-controlled trial of indobufen in the prophylaxis of migraine. Acta Neurol Scand 1988; 77 (6): 433-6
186. Stensrud P, Sjaastad O. Clinical trial of a new anti-bradykinin, anti-inflammatory drug, ketoprofen (19.583 r.p.) in migraine prophylaxis. Headache 1974; 14 (2): 96-100
187. Pradalier A, Vincent D. Migraine and non-steroidal anti-inflammatory agents [in French]. Pathol Biol (Paris) 1992; 40 (4): 397-405
188. Mikkelsen BM, Falk JV. Prophylactic treatment of migraine with tolfenamic acid: a comparative double-blind crossover study between tolfenamic acid and placebo. Acta Neurol Scand 1982; 66 (1): 105-11
189. Johnson RH, Hornabrook RW, Lambie DG. Comparison of mefenamic acid and propranolol with placebo in migraine prophylaxis. Acta Neurol Scand 1986; 73 (5): 490-2
190. Naesdal J, Brown K. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options. Drug Saf 2006; 29 (2): 119-32
191. Zwart JA, Dyb G, Hagen K, et al. Analgesic use: a predictor of chronic pain and medication overuse headache: the Head-HUNT Study. Neurology 2003; 61 (2): 160-4
192. Bigal ME, Rapoport AM, Sheftell FD, et al. Transformed migraine and medication overuse in a tertiary headache centre: clinical characteristics and treatment outcomes. Cephalalgia 2004; 24 (6): 483-90
193. Relja G, Granato A, Maria Antonello R, et al. Headache induced by chronic substance use: analysis of medication overused and minimum dose required to induce headache. Headache 2004; 44 (2): 148-53
194. Limmroth V, Katsarava Z. Medication overuse headache. Curr Opin Neurol 2004; 17 (3): 301-6
195. Colas R, Munoz P, Temprano R, et al. Chronic daily headache with analgesic overuse: epidemiology and impact on quality of life. Neurology 2004; 62 (8): 1338-42
196. Pfaffenrath V, Wessely P, Meyer C, et al. Magnesium in the prophylaxis of migraine: a double-blind placebo-controlled study. Cephalalgia 1996; 16 (6): 436-40
197. Pittler MH, Ernst E. Feverfew for preventing migraine. Cochrane Database Syst Rev 2004; (1): CD002286
198. Boehnke C, Reuter U, Flach U, et al. High-dose riboflavin treatment is efficacious in migraine prophylaxis: an open study in a tertiary care centre. Eur J Neurol 2004; 11 (7): 475-7
199. Mauskop A. Alternative therapies in headache: is there a role? Med Clin North Am 2001; 85 (4): 1077-84
200. Bianchi A, Salomone S, Caraci F, et al. Role of magnesium, coenzyme Q10, riboflavin, and vitamin B12 in migraine prophylaxis. Vitam Horm 2004; 69: 297-312
201. Rios J, Passe MM. Evidenced-based use of botanicals, minerals, and vitamins in the prophylactic treatment of migraines. J Am Acad Nurse Pract 2004; 16 (6): 251-6
202. Maizels M, Blumenfeld A, Burchette R. A combination of riboflavin, magnesium, and feverfew for migraine prophylaxis: a randomized trial. Headache 2004; 44 (9): 885-90
203. Sandor PS, Di Clemente L, Coppola G, et al. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 2005; 64 (4): 713-5
204. Coenzyme Q10 [published erratum appears in Med Lett Drugs Ther 2006; 48 (1230): 24]. Med Lett Drugs Ther 2006; 48 (1229): 19-20
205. Sandor PS, Afra J. Nonpharmacologic treatment of migraine. Curr Pain Headache Rep 2005; 9 (3): 202-5
206. Troost BT. Botulinum toxin type A (Botox) in the treatment of migraine and other headaches. Expert Rev Neurother 2004; 4 (1): 27-31
207. Evers S, Vollmer-Haase J, Schwaag S, et al. Botulinum toxin A in the prophylactic treatment of migraine: a randomized, double-blind, placebo-controlled study. Cephalalgia 2004; 24 (10): 838-43
208. Gobel H. Botulinum toxin in migraine prophylaxis. J Neurol 2004; 251 Suppl. 1: 8I-11I
209. Conway S, Delplanche C, Crowder J, et al. Botox therapy for refractory chronic migraine. Headache 2005; 45 (4): 355-7
210. Aoki KR. Evidence for antinociceptive activity of botulinum toxin type A in pain management. Headache 2003; 43 Suppl. 1: 9S-15S
211. Cui M, Khanijou S, Rubino J, et al. Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 2004; 107 (1-2): 125-33
212. Durham PL, Cady R, Cady R. Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy. Headache 2004; 44 (1): 35-42
213. Blumenfeld AM, Binder W, Silberstein SD, et al. Procedures for administering botulinum toxin type A for migraine and tension-type headache. Headache 2003; 43 (8): 884-91
214. Nissan GR, Diamond ML. Advances in migraine treatment. J Am Osteopath Assoc 2005; 105 (4 Suppl. 2): 9S-15S
215. Mathew NT, Kaup AO. The use of botulinum toxin type A in headache treatment. Curr Treat Options Neurol 2002; 4 (5): 365-73
216. Neri I, Granella F, Nappi R, et al. Characteristics of headache at menopause: a clinico-epidemiologic study. Maturitas 1993; 17 (1): 31-7
217. Johnson CJ. Headache in women. Prim Care 2004; 31 (2): 417-28
218. Calhoun AH. Migraine and menopause [letter]. Headache 2004; 44 (1): 106
219. Matharu MS, Levy MJ, Goadsby PJ. Understanding migraine in women [published erratum appears in Practitioner 2002; 246 (1638): 618]. Practitioner 2002; 246 (1633): 272-8
220. Fettes I. Migraine in the menopause. Neurology 1999; 53 (4 Suppl. 1): 29S-33S
221. Facchinetti F, Nappi RE, Tirelli A, et al. Hormone supplementation differently affects migraine in postmenopausal women [published erratum appears in Headache 2003; 43 (2): 172; Headache 2003; 43 (3): 310]. Headache 2002; 42 (9): 924-9
222. Silberstein SD. Hormone-related headache. Med Clin North Am 2001; 85 (4): 1017-35
223. Heikkinen J, Vaheri R, Timonen U. Long-term safety and tolerability of
224. Felmeden DC, Lip GY. Hormone replacement therapy and hypertension. Blood Press 2000; 9 (5): 246-9
225. Sitruk-Ware R. Progestogens in hormonal replacement therapy: new molecules, risks, and benefits. Menopause 2002; 9 (1): 6-15
226. Gambacciani M, Monteleone P, Sacco A, et al. Hormone replacement therapy and endometrial, ovarian and colorectal cancer. Best Pract Res Clin Endocrinol Metab 2003; 17 (1): 139-47
227. Prelevic GM, Kocjan T, Markou A. Hormone replacement therapy in postmenopausal women. Minerva Endocrinol 2005; 30 (1): 27-36
228. Nelson HD, Humphrey LL, Nygren P, et al. Postmenopausal hormone replacement therapy: scientific review. JAMA 2002; 288 (7): 872-81
229. Ashkenazi A, Silberstein SD. Hormone-related headache: pathophysiology and treatment. CNS Drugs 2006; 20 (2): 125-41
230. Kudrow L. The relationship of headache frequency to hormone use in migraine. Headache 1975; 15 (1): 36-40
231. Hargrove JT, Maxson WS, Wentz AC, et al. Menopausal hormone replacement therapy with continuous daily oral micronized estradiol and progesterone. Obstet Gynecol 1989; 73 (4): 606-12
232. Nand SL, Webster MA, Baber R, et al. Menopausal symptom control and side-effects on continuous estrone sulfate and three doses of medroxyprogesterone acetate. Ogen/Provera Study Group. Climacteric 1998; 1 (3): 211-8
233. Nappi RE, Cagnacci A, Granella F, et al. Course of primary headaches during hormone replacement therapy. Maturitas 2001; 38 (2): 157-63
234. Greenblatt RB. The use of androgens in the menopause and other gynecic disorders. Obstet Gynecol Clin North Am 1987; 14 (1): 251-68
235. Smallwood GH, Meador ML, Lenihan JP, et al. Efficacy and safety of a transdermal contraceptive system. Obstet Gynecol 2001; 98 (5 Pt 1): 799-805
236. Adler G, Young D, Galant R, et al. A multicenter, open-label study to evaluate satisfaction and menopausal quality of life in women using transdermal estradiol/norethindrone acetate therapy for the management of menopausal signs and symptoms. Gynecol Obstet Invest 2005; 59 (4): 212-9
237. Silberstein SD. Headache and female hormones: what you need to know. Curr Opin Neurol 2001; 14 (3): 323-33
238. Merle L, Laroche ML, Dantoine T, et al. Predicting and preventing adverse drug reactions in the very old. Drugs Aging 2005; 22 (5): 375-92
239. Ward TN. Headache disorders in the elderly. Curr Treat Options Neurol 2002; 4 (5): 403-8